Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

We're Hiring: Senior Translational Pharmacologist–Ophthalmology

June 8, 2026
Pharmidex is seeking an experienced and driven Principal / Senior Translational Pharmacologist to join our growing Translational Research team and lead innovative ophthalmology programmes. We're looking for a senior scientist with expertise in ophthalmology, ocular disease models, and translational pharmacology who is ready to make a real impact in a dynamic CRO environment. ✅ Competitive salary and benefits ✅ High-visibility scientific leadership role ✅ Opportunities to present at international conferences ✅ Direct impact on advancing innovative medicines toward the clinic

We proudly celebrate 24 years of Pharmidex!!!

May 26, 2026
What started in 2002 with a small team and a handful of clients has grown into a global preclinical CRO trusted by more than 400 clients worldwide, including many leading pharmaceutical and biotechnology companies. Our commitment to delivering bespoke and standard study designs in a quick, expert, and cost-effective manner has allowed us to support more than 1,000 studies per year for multiple consecutive years, something we are incredibly proud of. Over the years, we have been fortunate to contribute data supporting numerous marketed drugs, numerous successful client acquisitions, and programmes successfully supporting patients. Most importantly, our success is a testament to the wider scientific community and the innovative ideas and projects our clients trust us to support every day. Thank you to every client, collaborator, colleague, and friend who has been part of our journey so far. We look forward to supporting the next generation of science and innovation for another 24 years.

Promotion of Dr. Martin Barrett to Chief Business Officer

May 20, 2026
We are delighted to announce the promotion of Dr. Martin Barrett to Chief Business Officer at Pharmidex . Martin brings more than 23 years of experience across the pharmaceutical and drug discovery sectors, combining deep scientific expertise with strategic commercial leadership. Throughout his career, he has played a key role in advancing translational science, building strategic partnerships and supporting innovative drug development programmes. In his new role, Martin will help drive Pharmidex’s continued growth, strengthen collaborations, and expand our capabilities across preclinical pharmacology, toxicology, translational science, and clinical development support. Congratulations to Martin on this well-deserved promotion. We look forward to the continued impact of his leadership across Pharmidex and the wider drug discovery community.
More Posts